AtriCure (ATRC) Invested Capital (2010 - 2026)

AtriCure (ATRC) has 17 years of Invested Capital data on file, last reported at $552.7 million in Q1 2026.

• Quarterly Invested Capital rose 7.01% year-over-year to $552.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $552.7 million (up 7.01% YoY) and the FY2025 annual result came in at $491.9 million, up 6.07% from the prior year.
• Invested Capital rose to $552.7 million in Q1 2026 per ATRC's latest filing, from $491.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $552.7 million in Q1 2026 and bottomed at $460.7 million in Q3 2022.
• The 5-year median for Invested Capital is $516.7 million (2022), against an average of $506.5 million.
• Peak annual rise in Invested Capital reached 34.18% in 2022, while the deepest fall reached 16.01% in 2022.
• Tracing ATRC's Invested Capital over 5 years: stood at $466.9 million in 2022, then increased by 1.8% to $475.3 million in 2023, then fell by 2.43% to $463.8 million in 2024, then increased by 6.07% to $491.9 million in 2025, then grew by 12.35% to $552.7 million in 2026.
• Per Business Quant, the three latest ATRC Invested Capital figures stand at $552.7 million (Q1 2026), $491.9 million (Q4 2025), and $538.4 million (Q3 2025).

Peer Comparison